contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  availableLanguages
  pageUrl
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


gubra-announces-discontinuation-of-development-of-nyp2-in-obesity-with-boehringer-ingelheim

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

availableLanguages

pageUrl

imgUrl

description

Gubra er en medicinalvirksomhed. Virksomhedens aktiviteter er fokuseret på de tidlige stadier af lægemiddeludvikling. De udfører hovedsageligt forskning og udvikling inden for stofskifte- og fibrotiske sygdomme.Virksomhedens produktportefølje omfatter flere brands og lægemidler, og aktiviteterne foregår på globalt plan med den største tilstedeværelse i Nordamerika og Norden. Hovedkontoret ligger i Hørsholm, Danmark.

Gubra

Today Gubra announces that Boehringer Ingelheim has decided to discontinue the development of the long-acting neuropeptide Y receptor type 2 (NPY2) agonist BI 1820237 in obesity. No further ...

<div class="mfn-preamble"><p><strong>Today Gubra announces that Boehringer Ingelheim has decided to discontinue the development of the long-acting neuropeptide Y receptor type 2 (NPY2) agonist BI 1820237 in obesity. No further information has been made available to Gubra.</strong></p></div><div class="mfn-body"><p>The other three projects in the successful partnership with Boehringer remain unaffected and continue as planned. This includes the development of the potential first-in-class triple agonist obesity treatment, which was advanced to Phase 1 clinical research in July of this year (<a rel="noopener" href="https://www.boehringer-ingelheim.com/external-link?external=https%3A%2F%2Fclassic.clinicaltrials.gov%2Fct2%2Fshow%2FNCT06352437">NCT06352437</a>) and two pre-clinical assets.</p></div><div class="mfn-footer mfn-contacts mfn-cffe77846134"><p><strong class="mfn-heading-1">Contacts at Gubra</strong><br>Media: Sofia Pitt Boserup, <a rel="noopener" href="mailto:sbo@gubra.dk">sbo@gubra.dk</a>, +45 4188 9586<br>Investors: Kristian Borbos, <a rel="noopener" href="mailto:kbo@gubra.dk">kbo@gubra.dk</a>, +45 3080 8035</p></div><div class="mfn-footer mfn-about mfn-a42358512560"><p><strong class="mfn-heading-1">About Gubra</strong><br>Gubra, founded in 2008 in Denmark, listed on NASDAQ Copenhagen, is specialized in pre-clinical contract research services and peptide-based drug discovery within metabolic and fibrotic diseases. Gubra’s activities are focused on the early stages of drug development and are organised in two business areas – CRO Services and Discovery &amp; Partnerships (D&amp;P). The two business areas are highly synergistic and create a unique entity capable of generating a steady cash flow from the CRO business while at the same time enjoying biotechnology upside in the form of potential development milestone payments and potential royalties from the D&amp;P business. In 2023, Gubra had approx. 220 employees and revenue of DKK 205 million. See <a rel="noopener" href="http://www.gubra.dk">www.gubra.dk</a> for more information.</p></div><div class="mfn-footer mfn-regulatory mfn-regulatory-mar"><p><em>This information is information that Gubra is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-10-31 11:07 CET.</em></p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong><br><a rel="noopener" href="https://storage.mfn.se/2c50a4eb-040c-43c5-8b97-2313cb0a44a1/gubra-announces-discontinuation-of-development-of-nyp2-in-obesity-with-boehringer-ingelheim.pdf" class="mfn-generated mfn-primary">Gubra announces discontinuation of development of NYP2 in obesity with Boehringer Ingelheim</a></p></div>

Gubra announces discontinuation of development of NYP2 in obesity with Boehringer Ingelheim

Tilmeld dig vores nyhedsbrev - ingen konto nødvendig!